Navigation Links
Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
Date:9/10/2013

mune disorders. Mr. Cooper served as executive vice president of finance and chief financial officer at Geron Corporation during 2012, a biopharmaceutical company focused on cancer therapies.  From 2006 to 2011, Mr. Cooper served as senior vice president, chief financial officer and treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity therapeutics.  Previously, Mr. Cooper held positions of increasing responsibility, including director, health care investment banking, at Deutsche Bank Securities, a leading global investment bank, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field.  Previously, he worked in audit and accounting services at Deloitte & Touche LLP, an independent registered public accounting firm, and was previously a C.P.A.  Mr. Cooper holds a B.A. in economics from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business. 

About Celladon
We are a clinical-stage biotechnology company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. MYDICAR, our most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with heart failure. In a 39-patient randomized, double-blind, placebo-controlled ph
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
2. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
5. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
6. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014
7. China Cord Blood Corporation to Report First Quarter of Fiscal 2014 Financial Results
8. Verenium Corporation To Announce Second Quarter 2013 Financial Results
9. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
10. Techne Corporation Announces Acquisition Completion
11. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... completed its review of QLT,USA, Inc.,s labeling supplement ... (G6PD) screening and blood monitoring,requirements., "We are ... remove,the need for blood monitoring from the Aczone ...
... Based on Increased 5-Year Survival Data for Responding ... Genta,Incorporated (OTC Bulletin Board: GNTA) announced that the ... Drug Administration (FDA) for its,New Drug Application (NDA) ... with relapsed or refractory chronic,lymphocytic leukemia (CLL). The ...
... from AHIMA, CHICAGO, June 5 "AHIMA,s Board ... promises to strengthen the effort,to address health IT from ... for senior executives. In addressing the need to,realize real ... critical,leadership challenge. AHIMA will continue working to support the ...
Cached Biology Technology:QLT announces positive Health Canada decision on Aczone(R) 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 3Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 4
(Date:7/9/2014)... Atlas (TCGA) Research Network have identified novel mutations ... the most common subtype of lung cancer. Knowledge ... of possible therapeutic targets for this disease and ... treatable mutations because many potent cancer drugs that ... jointly funded and managed by the National Cancer ...
(Date:7/9/2014)... that can attack soybean crops, why would charcoal rot ... University of Illinois scientists cite the earth,s changing climate ... the fungus that causes charcoal rot. , Fungi may ... Macrophomina phaseolina , the fungus that causes charcoal ... the climate continues to change and we see more ...
(Date:7/9/2014)... with pain and fever but often can be defeated with ... and hard to beat. Now, scientists have built a new ... pyramids. Published in the journal ACS Applied Materials & ... and kill more of them than medicine alone. , David ... can lie in wait, undetectable in the human body or ...
Breaking Biology News(10 mins):Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... North Hollywood, CA August 13, 2009 - The ... and support for myeloma patients, families, researchers and physicianstoday ... link between environmental toxins and bone disease in multiple ... of cells in the bone marrow that affect production ...
... the splendidly colorful leaves adorning the trees are a delight ... yellow, while the United States and East Asia boast lustrous ... differences in autumnal hues around the world? A new theory ... Education- Biology at the University of Haifa-Oranim and Prof. Jarmo ...
... deaths has declined steadily in the last three decades. ... age groups have shown some improvement, according to a ... of the American Association for Cancer Research. ... better treatment, have resulted in profound gains, but these ...
Cached Biology News:New study suggests possible genetic links between environmental toxins and multiple myeloma 2Why are autumn leaves red in America and yellow in Europe? 2Why are autumn leaves red in America and yellow in Europe? 3Cancer mortality rates experience steady decline 2
...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
Biology Products: